Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Henan Cancer Hospital

Status: Enrolling

Conditions: Marginal Zone Lymphoma

Treatments: Drug: Rituximab; Drug: Zanubrutinib

Study type: Observational

Funder types: Other

Identifiers

NCT07233720

HNSZLYYNHL10

Details and patient eligibility

About

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Enrollment: 30 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with CD20-positive marginal zone lymphoma diagnosed by histopathology
2. First-line treatment with the combination regimen of zanubrutinib and rituximab
3. No receiving systematic treatment before enrollment
4. Having at least one measurable lesions. Measurable lesions were defined as: the longest diameter of lymph node lesions in CT cross-sectional images > 1.5 cm, or the longest diameter of the extranodal lesion is greater than 1.0cm
5. The patients voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.

Exclusion criteria

1. Other malignant tumor history or active malignant tumor need be treated
2. In addition to zanubrutinib and rituximab, other anti-tumor drug treatments were also received simultaneously (except for glucocorticoids aimed at controlling symptoms before formal treatment).

Trial design

30 participants in 1 patient group

Zanubrutinib Combined With Rituximab

Description:

Induction treatment: Rituximab, 375mg/m2, Intravenous administration on day 1 (21 days/cycle); Zanubrutinib, 160mg twice daily continuous oral administration from 1 to 8 cycles (21 days/cycle) Maintenance treatment: Zanubrutinib, 160mg twice daily continuous oral administration for two years (28 days/cycle)

Treatment:

Drug: Zanubrutinib

Drug: Rituximab